133 related articles for article (PubMed ID: 35934632)
1. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.
Ahmed G; Bhasin-Chhabra B; Szabo A; Shah NN; Longo W; Dhakal B; Chhabra S; D'Souza A; Fenske TS; Hamadani M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):863-868. PubMed ID: 35934632
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
3. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
Gutgarts V; Jain T; Zheng J; Maloy MA; Ruiz JD; Pennisi M; Jaimes EA; Perales MA; Sathick J
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1071-1076. PubMed ID: 32088364
[TBL] [Abstract][Full Text] [Related]
4. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Gupta S; Seethapathy H; Strohbehn IA; Frigault MJ; O'Donnell EK; Jacobson CA; Motwani SS; Parikh SM; Curhan GC; Reynolds KL; Leaf DE; Sise ME
Am J Kidney Dis; 2020 Jul; 76(1):63-71. PubMed ID: 31973908
[TBL] [Abstract][Full Text] [Related]
5. Association of pre-operative chronic kidney disease and acute kidney injury with in-hospital outcomes of emergency colorectal surgery: a cohort study.
Miyake K; Iwagami M; Ohtake T; Moriya H; Kume N; Murata T; Nishida T; Mochida Y; Isogai N; Ishioka K; Shimoyama R; Hidaka S; Kashiwagi H; Kawachi J; Ogino H; Kobayashi S
World J Emerg Surg; 2020 Mar; 15(1):22. PubMed ID: 32216810
[TBL] [Abstract][Full Text] [Related]
6. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.
León-Román J; Iacoboni G; Bermejo S; Carpio C; Bolufer M; García-Carro C; Sánchez-Salinas M; Alonso-Martínez C; Bestard O; Barba P; Soler MJ
Clin Kidney J; 2024 Mar; 17(3):sfae027. PubMed ID: 38500492
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy.
Farooqui N; Sy-Go JPT; Miao J; Mehta R; Vaughan LE; Bennani NN; Wang Y; Bansal R; Hathcock MA; Hayman SR; Johnston PB; Villasboas JC; Paludo J; Ansell SM; Leung N; Lin Y; Herrmann SM
Mayo Clin Proc; 2022 Jul; 97(7):1294-1304. PubMed ID: 35787856
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Lyu Y; Zhang M; Wei G; Ding S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):137-143. PubMed ID: 36161296
[TBL] [Abstract][Full Text] [Related]
10. Long-term fate of renal function after open surgery for juxtarenal and pararenal aortic aneurysm.
Sugimoto M; Takahashi N; Niimi K; Kodama A; Banno H; Komori K
J Vasc Surg; 2018 Apr; 67(4):1042-1050. PubMed ID: 28964618
[TBL] [Abstract][Full Text] [Related]
11. Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review.
Khan I; Khan N; Wolfson N; Djebabria K; Rehman MEU; Anwer F
Clin Hematol Int; 2023 Jun; 5(2-3):122-129. PubMed ID: 37010812
[TBL] [Abstract][Full Text] [Related]
12. Acute Kidney Injury in Subjects With Chronic Kidney Disease Undergoing Total Joint Arthroplasty.
Soliman KM; Campbell RC; Fülöp T; Goddard T; Pisoni R
Am J Med Sci; 2019 Jul; 358(1):45-50. PubMed ID: 31079840
[TBL] [Abstract][Full Text] [Related]
13. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
14. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Stolz S; Roncador M; Rösler W; Zenz T; Manz MG; Müller AMS; Widmer CC
Swiss Med Wkly; 2022 Jun; 152():w30186. PubMed ID: 35752964
[TBL] [Abstract][Full Text] [Related]
15. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
16. Dialysis Requirement and Long-Term Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease and Superimposed Acute Kidney Injury.
Omotoso BA; Turgut F; Abdel-Rahman EM; Xin W; Ma JZ; Scully KW; Arogundade FA; Balogun RA
Nephron; 2017; 136(2):95-102. PubMed ID: 28249270
[TBL] [Abstract][Full Text] [Related]
17. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy.
Wang X; Qi Y; Li H; Liu F; Cao J; Chen W; Wang Y; Qi K; Yan Z; Zhu F; Li Z; Cheng H; Xu K
Front Immunol; 2022; 13():943004. PubMed ID: 36081517
[TBL] [Abstract][Full Text] [Related]
18. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J; Nizamuddin I; Epperla N; David K; Cohen JB; Moyo TK; Ollila T; Hess B; Roy I; Ferdman R; Liu J; Chowdhury SM; Romancik J; Bhansali RS; Harris EI; Sorrell M; Masel R; Kittai AS; Denlinger N; Sigmund AM; Fitzgerald L; Galvez C; Ma S; Winter J; Pro B; Gordon LI; Danilov A; Stephens D; Shah NN; Kenkre V; Barta SK; Torka P; Shouse G; Karmali R
Blood Adv; 2023 Jun; 7(12):2657-2669. PubMed ID: 36094847
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
20. Fenestrated-branched endovascular aortic repair in patients with chronic kidney disease.
Khoury MK; Timaran DE; Soto-Gonzalez M; Timaran CH
J Vasc Surg; 2020 Jul; 72(1):66-72. PubMed ID: 32063447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
